Cabaletta Bio, Inc.
$3.31
▲
10.45%
2026-04-21 05:51:01
www.cabalettabio.com
NMS: CABA
Explore Cabaletta Bio, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$382.95 M
Current Price
$3.31
52W High / Low
$3.78 / $1.06
Stock P/E
—
Book Value
$1.11
Dividend Yield
—
ROCE
-149.87%
ROE
-1.27%
Face Value
—
EPS
$-2.1
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
154
Beta
3.29
Debt / Equity
24.18
Current Ratio
2.77
Quick Ratio
2.77
Forward P/E
-2.23
Price / Sales
—
Enterprise Value
$241.94 M
EV / EBITDA
-1.42
EV / Revenue
—
Rating
Buy
Target Price
$13.12
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Black Diamond Therapeutics, Inc. | $3.05 | 7.84 | $175.3 M | — | 15.61% | 22.88% | $4.94 / $1.31 | $1.96 |
| 2. | Lyell Immunopharma, Inc. | $24.89 | — | $559.6 M | — | -69.37% | -86.98% | $45 / $7.65 | $11.68 |
| 3. | Werewolf Therapeutics, Inc. | $0.97 | — | $45.96 M | — | -182.5% | -1.24% | $2.38 / $0.53 | $0.51 |
| 4. | Aditxt, Inc. | $0.35 | — | $0.39 M | — | -318.91% | -6.99% | $2,594.48 / $0.39 | $-151.87 |
| 5. | Karyopharm Therapeutics Inc. | $8.94 | — | $193.06 M | — | -554.58% | 81.86% | $10.99 / $3.65 | $-16 |
| 6. | Evogene Ltd. | $0.8 | — | $7.92 M | — | -84.53% | -1.01% | $2.42 / $0.72 | $-0.01 |
| 7. | MacroGenics, Inc. | $3.48 | — | $228.17 M | — | -34.08% | -86.94% | $3.88 / $1.11 | $0.88 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -42.61 M | -46.59 M | -45.91 M | -37.14 M | -33.78 M | — |
| Net Profit | -41.92 M | -44.87 M | -45.13 M | -35.94 M | -32.59 M | — |
| EPS in Rs | -0.38 | -0.4 | -0.41 | -0.32 | -0.29 | -0.62 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -172.24 M | -125.14 M | -74.66 M | -54.14 M |
| Net Profit | -167.86 M | -115.86 M | -67.67 M | -52.98 M |
| EPS in Rs | -1.51 | -1.04 | -0.61 | -0.48 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 165.08 M | 185.05 M | 253.65 M | 116.97 M |
| Total Liabilities | 53.03 M | 32.71 M | 17.45 M | 12.45 M |
| Equity | 112.05 M | 152.34 M | 236.2 M | 104.52 M |
| Current Assets | 138.87 M | 166.68 M | 244.49 M | 108.83 M |
| Current Liabilities | 50.15 M | 27.09 M | 15.99 M | 9.49 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -131.08 M | -88.22 M | -53.55 M | -46.38 M |
| Investing CF | -50.27 M | 47.29 M | -22.45 M | -27.22 M |
| Financing CF | 100.35 M | 11.68 M | 187.63 M | 32.98 M |
| Free CF | -132.31 M | -90.43 M | -54.24 M | -48.83 M |
| Capex | -1.23 M | -2.21 M | -0.69 M | -2.45 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -71.21% | -27.75% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.